Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth +22 more·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 601–700 of 1,013

Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study
Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Gaik Ming Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Chen Lung Tan, Sanchalika Acharyya, Kiat Hoe Ong · 2024 · Clinical Hematology International
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
Nadine H. Abdallah, Shaji Kunnathu Kumar · 2024 · Journal of the National Comprehensive Cancer Network
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes
Maria Teresa Petrucci, Sara Bringhen, Cristina Entrala Cerezo, João Mendes, Patrizio Armeni · 2024 · Hematology
Treatment of elderly and frail myeloma patients
Steven Chun-Min Shih, Alissa Visram, Hira S. Mian · 2024 · La Presse Médicale
Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience
Dor Shpitzer, Yael Chava Cohen, Tamir Shragai, Ori Grossberger, Dana Amsterdam, Anat Reiner Benaim, Irit Mazza Avivi · 2025 · Blood Advances
Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two‐centre Australian experience
Jeremy Er, David J. M. Routledge, Jennifer Hempton · 2021 · Internal Medicine Journal
Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation—A Blood or Marrow Transplant Survivor Study Report
Smith Giri, Yanjun Chen, Jessica Wu, Lindsey Hageman, Joshua Richman, Liton Francisco, Wendy Landier, Luciano J. Costa, Andrew Michael McDonald, Donna L. Murdaugh et al. · 2021 · Transplantation and Cellular Therapy
SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma
Shakira Jeanene Grant, Girija Joshi, Brea C. Lipe · 2021 · Clinical Lymphoma Myeloma & Leukemia
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
Monica Epstein, Candis Morrison · 2022 · Seminars in Oncology
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematologica Pugliese’
Giuseppe Mele, Nicola Cascavilla, Nicola Di Renzo et al. · 2022 · Annals of Hematology
Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?
Joana Caetano, Filipa Barahona, Paulo Lúcio, Cristina M. Joao · 2022 · Hemato
Monocyte or white blood cell counts and β 2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki� Ito, Shin‐ichi Fuchida, Hitoji Uchiyama et al. · 2022 · Therapeutic Advances in Hematology
Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review
Pasquale B. Esposito, Daniela Picciotto, Francesca Costigliolo · 2023 · Frontiers in Medicine
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
Anna Furlan, Michele Cea, Laura Pavan, Mónica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca F. Patriarca, Claudia Minotto et al. · 2024 · Cancer Medicine
Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma
Richard LeBlanc, Kevin Song, Darrell J. White, Anna Christofides, Sarah Doucette · 2019 · Current Oncology
Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence
Pellegrino Musto, Francesco La Rocca · 2020 · Expert Review of Hematology
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma
Al-Ola A. Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Shebli Atrash, Hameem I. Kawsar, Monia Sigle, Leyla Osman Shune, Joseph P. McGuirk, Siddhartha Ganguly · 2020 · Clinical Lymphoma Myeloma & Leukemia
A 9‐year‐old male with Barth syndrome and cardiac transplant presenting with hyperviscosity syndrome caused by EBV‐negative plasmacytoid posttransplant lymphoproliferative disorder
Yixian Li, Rachel Offenbacher, Nicolas Corral · 2021 · Pediatric Blood & Cancer
Progressive multifocal leukoencephalopathy in multiple myeloma associated with daratumumab, lenalidomide, and dexamethasone
Kento Seko, Yuto Uchida, Takashi Kanamori · 2022 · Neurology and Clinical Neuroscience
New daratumumab quadruplets and triplets for newly diagnosed MM
David Killock · 2019 · Nature Reviews Clinical Oncology
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
Barry A. Paul, Shebli Atrash, Manisha Bhutani, Peter Michael Voorhees, Issam S. Hamadeh, Saad Z. Usmani · 2020 · Expert Review of Hematology
Immunosuppression in Patients With Primary Immunodeficiency—Walking the Line
Syed Shahzad Mustafa, Nicholas L. Rider, Stephen R.A. Jolles · 2022 · The Journal of Allergy and Clinical Immunology In Practice
Minimal residual disease negative: A novel endpoint for accelerated approval; What providers should know
Sruthi Ranganathan, Vinay K. Prasad · 2025 · Journal of Cancer Policy
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
Laahn H. Foster, Larry Don Anderson, Alfred Chung, Chakra P. Chaulagain, Erin M. Pettijohn, Andrew J. Cowan, Caitlin L. Costello, Sarah Larson, Douglas Weston Sborov, Kenneth H. Shain et al. · 2025 · Blood Cancer Journal
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Mario Boccadoro, Angelo Belotti, Felice Bombaci, Sara Bringhen, Gabriele Buda, Anna Maria Cafro, Michele Caimmi, Beatrice Canali, Pier Luigi Canonico, Michèle Cavo et al. · 2025 · BMC Cancer
Reshaping multiple myeloma treatment: recent breakthroughs
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio et al. · 2025 · Expert Opinion on Pharmacotherapy
MRD in multiple myeloma: the clinical perspective
Tommaso Caravita di Toritto, Angela Rago · 2026 · Frontiers in Oncology
Daratumumab in transplant regimens for myeloma?
Jean Luc Harousseau, Mohamad Mohty · 2020 · Blood
Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab
Vandana Baloda, Michael R Shurin, Sarah Wheeler · 2021 · The Journal of Applied Laboratory Medicine
Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review
Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron Michael Goodman, Rajshekhar Chakraborty, Douglas Weston Sborov, Samuel M. Rubinstein, Ghulam Rehman Mohyuddin · 2023 · European Journal Of Haematology
Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
Richard LeBlanc, Hira S. Mian, Donna Ellen Reece et al. · 2023 · European Journal Of Haematology
Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
Yuichi Horigome, Kazuhito Suzuki, Takahiro Suzuki · 2024 · Life
Az elérhető gyógyulás küszöbén: innovációk a myeloma multiplex kezelésében
Tünde Tóth, Hussain Alizadeh · 2024 · Orvosi Hetilap
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel
Rafaël Fonseca, Adriana Rossi, Rohan Medhekar, Jennifer Voelker, Trevor Homan, Jessica Wilcock, Anna Karakusevic, James Cochrane, Daisy Bridge, Richard Perry et al. · 2024 · Future Oncology
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk
Damian Mikulski, Marcin Kamil Kędzior, Grzegorz Mirocha, Katarzyna Jerzmanowska, Żaneta Witas, Łukasz Woźniak, Magdalena Pawlak, Kacper Kościelny, Michał Kośny, Pawel J. Robak et al. · 2024 · Cancers
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies
Luciano J. Costa, Francesca Gay, Ola Landgren, María‐Victoria Mateos, Philippe Moreau, Cyrille Touzeau, Franziska Ertel, Ian McFadden, Rani Najdi, Katja Christina Weisel · 2025 · Annals of Hematology
Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
Hexiang Bai, Chunlan Zhang, Ailin Zhao, Wenjiao Tang, Li Zhang · 2025 · Therapeutic Advances in Hematology
Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironment
Jahangir Abdi, Payman Nasr · 2025 · Frontiers in Hematology
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐ CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Laure Vincent, Olivier Decaux, Aurore Perrot, Bruno Royer, Thomas Chalopin, Arthur Bobin, Margaret Macro, Denis Caillot, Lionel Karlin, Caroline Jacquet et al. · 2025 · Cancer Medicine
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study
Alexis Talbot, Cyrille Hulin, Aurore Perrot et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
Current and Future Directions of Immunotherapies in Multiple Myeloma
Eden Ayele Biltibo, Malini Surapaneni, Samer Al Hadidi, Attaya Suvannasankha, Reena Jayani · 2025 · American Society of Clinical Oncology Educational Book
Rational engineering of degradation tail-driven CELMoD–antibody conjugates for precision malignancy therapy
Yu Lian Guo, Yi Song, Hanlin Wang, Lu Yang, Jingyu Zhang, Zheyuan Shen, Weijuan Kan, Yuxian Wang, Haiting Duan, Shuangshuang Geng et al. · 2025 · Acta Pharmaceutica Sinica B
Carfilzomib in Combination with Daratumumab in the Management of Relapsed Multiple Myeloma
Cyrille Touzeau, Chloé Antier, Philippe Moreau · 2020 · Future Oncology
Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78
Mark Aaron Fiala, Justin A. King, Daniel Feinberg · 2021 · Bone Marrow Transplantation
A Novel Model of Tumor-Infiltrating B Lymphocyte Specific RNA-Binding Protein-Related Genes With Potential Prognostic Value and Therapeutic Targets in Multiple Myeloma
Jingjing Zhang, Pengcheng He, Xiaoning Wang, Suhua Wei, Le Ma, Jing Zhao · 2021 · Frontiers in Genetics
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Alana L. Keller, Daniel W. Sherbenou, Peter A. Forsberg, Tomer Martin Mark · 2022 · Frontiers in Oncology
Case for More Autologous Transplants in Myeloma in Resource-Constrained Settings
Suvir Singh, Rintu Sharma · 2022 · Indian Journal of Medical and Paediatric Oncology
Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
Francesca Farina, Valeria Ferla, Sarah Marktel, D. Clerici, Sara Mastaglio, Tommaso Perini, C. Oltolini, Raffaella Greco, F. Aletti, Andrea Angelo Assanelli et al. · 2022 · Frontiers in Oncology
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Martin Štork, Sabina Ševčı́ková, Tomáš Jelı́nek, Jiří Minařík, Jakub Radocha, Tomáš Pika, Lenka Pospíšilová, Ivan Špıčka, Jan Štraub, Petr Pavlíček et al. · 2022 · Biomedicines
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study
Ari Pelcovits, Peter M. Barth, John Leonard Reagan, Adam J. Olszewski, Vallerie Rosati, Roxanne Wood, Ashlee Sturtevant, Eric S. Winer · 2023 · The Oncologist
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Julie Stakiw, Shruthi Ganeshappa Kodad, Richard LeBlanc, Michaël Sébag, Annette E. Hay, Vishal Kukreti, Julie Anne Côté, Fernando Camacho, Molei Fu, Engin Gul et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
Kelsey Beck, Tyler B. Sandahl, Sikander Ailawadhi, Nandita Khera, Chelsee J. Jensen · 2023 · Current Hematologic Malignancy Reports
Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer
Sheng Chen, Xiangrong Li, Wen Ao · 2024 · BMC Women s Health
Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study
Li Bao, Yutong Wang, Peng Liu et al. · 2024 · EClinicalMedicine
A Rare Case of Daratumumab-Associated Encephalopathy in Multiple Myeloma
Jingjing Xiang, Zirui Hong, Yu Zhang, Junfa Chen, Jianping Shen, Ni Zhu · 2024 · Immunotherapy
Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy
Qing Hua Zhang, Yi Dong, Zhimin Zhai · 2024 · Acta Haematologica
Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma
Hideki Uryu, Yuko Matsumoto Mishima, Yuko Ishihara · 2024 · Journal of the Japan Society of the Reticuloendothelial System
Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report
Masataka Sakashita, Naohi Sahara, Jun Aoki, Takashi Matsunaga, Seiichiro Kobayashi, Shinsuke Kitahara, Tomoki Fujii, Nobuhiro Ohno · 2024 · Oncology Letters
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
Giuseppe Mele, Daniele Derudas, Concetta Conticello, Gregorio Barilà, Massimo Gentile, Stefano Rocco, Salvatore Palmieri, Giulia Palazzo, Candida Germano, Giovanni Reddiconto et al. · 2024 · Annals of Hematology
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
Dominik Fric, Martin Štork, Ivanna Boichuk et al. · 2024 · European Journal Of Haematology
Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region
Mahmoud Marashi, Khalil Al Farsi, Hussni Al-Hateeti, Ahmad Alhuraiji, Hesham Elsabah, Honar Cherif, Anas Ahmad Hamad, Kayane Mheidly, Hani Yousif Osman, Mohamad Mohty · 2025 · Clinical Hematology International
Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma
Albert Oriol, Gladys Ibarra, Eugènia Abella, Cristina Motlló, María Teresa Cibeira, Antoni García, Lourdes Escoda, Miquel Granell, Randa Ben Azaiz, Marta Cervera et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
Andrew R. Belch, Nizar Jacques Bahlis, Darrell J. White, Matthew C. Cheung, Christine I. Chen, Chaim Shustik, Kevin Song, Axel Tosikyan, Angela A. Dispenzieri, Kenneth Carl Anderson et al. · 2020 · Cancer Medicine
Anti-body building: The exercise of advancing immune based myeloma therapies
Joshua Ryan Richter, Santiago Thibaud · 2020 · Blood Reviews
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Giuseppe Bertuglia, Lorenzo Cani, Alessandra Larocca, Francesca Gay, Mattia D’Agostino · 2022 · International Journal of Molecular Sciences
Efficacy and tolerability of VCD chemotherapy in a UK real‐world dataset of elderly transplant‐ineligible newly diagnosed myeloma patients
Alexandros Rampotas, Faouzi Djebbari, Fotios P. Panitsas, Charlotte Lees, Ismini Tsagkaraki, Ana Rita Gomes, Steve Prideaux, Lucia Chen, Catherine F. Prodger, Akhil Khera et al. · 2021 · European Journal Of Haematology
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis
Abdullah S. Al Saleh, Alissa Visram, Harsh Vallabh Parmar, Eli Muchtar, Francis K. Buadi, Angela A. Dispenzieri, Rahma M. Warsame, Martha Q. Lacy, David Dingli, Nelson Leung et al. · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
Management of Multiple Myeloma in Older Patients
Jian Li, Henry Siu Him Chan · 2021 · EMJ Hematology
Sustained minimal residual disease in myeloma
Giada Bianchi · 2022 · Blood
A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma ( AMaRC 01‐16)
Andrew G Spencer, Anna Kalff, Jake Shortt, Hang Quach, Craig Thomas Wallington-Beddoe, John Reynolds, Patricia Walker, Simon James Harrison, Rosanne D. Dunn, Cameron J. Wellard · 2023 · British Journal of Haematology
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
Adrián Macías Alegre, Javier de la Rubia, Anna Maria Sureda, Cristina Encinas Rodríguez, Alexia Suárez, María Jesús Blanchard, Joan Bargay, Paula Rodríguez‐Otero, Andrés Insunza, Luis Palomera et al. · 2020 · HemaSphere
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
Hélène Gardeney, Arthur Bobin, Cécile Gruchet, Florence Sabirou, Anthony Lévy, Laly Nsiala, Laura Cailly, Cécile Tomowiak, José Miguel Torregrosa Diaz, Niels Moya et al. · 2020 · Journal of Clinical Medicine
Value in Myeloma Care: Myth or Reality
Evguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin · 2022 · Current Hematologic Malignancy Reports
Approaches to Treating Multiple Myeloma, Now and Moving Forward
Vikas Anand Gupta, Nisha S. Joseph, Ajay K. Nooka · 2020 · JCO Oncology Practice
Subcutaneous versus intravenous daratumumab in multiple myeloma – Authors' reply
María‐Victoria Mateos, Saad Z. Usmani · 2020 · The Lancet Haematology
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma
Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin T. Diamond, Paolo Corradini et al. · 2023 · medRxiv
Analysis of Multiple Myeloma Drug Efficacy
Alexandre Matov · 2024 · medRxiv
High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients
Yi L. Hwa, Dragan Jevremović, Shaji Kunnathu Kumar et al. · 2023 · British Journal of Haematology
Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
Anas Ahmad Hamad, Shereen Elazzazy, Ruba Yasin Taha et al. · 2024 · Journal of health economics and outcomes research
Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
Yan Wang, Yuanfang Liu, Shiwei Jin, Tao Yi, Weiping Zhang, Jianlin Chen, Songfu Jiang, Jian‐Qing Mi · 2025 · Scientific Reports
CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention
Colleen Isabelle, Amy E Boles, Kathleen K. McConnell, Robyn Keller, Rachel Burzinski, Zachary Hutchins, Giulia Calabretto, Lara Cheslow, Jonathan Xu, Nitin Chakravarti et al. · 2025 · Leukemia
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter Michael Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas Weston Sborov, Meletios Athanasios Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew G Spencer et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention
Cristina Encinas, María Jesús Blanchard, Rafael Alonso, José‐Ángel Hernández‐Rivas, Rafael Ríos Tamayo, Marina Machado-Vílchez, Joaquín Martínez‐López, María‐Victoria Mateos · 2025 · Clinical Lymphoma Myeloma & Leukemia
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Alessandra Larocca, Sonia Ronconi, Claudia Cellini, Antonietta Pia Falcone, Fabrizio Accardi et al. · 2025 · The Lancet Haematology
Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database
Michihide Tokuhira, Hitomi Nakayama, Kohtaro Toyama et al. · 2025 · International Journal of Hematology
Treatment of transplant-ineligible multiple myeloma
Jongheon Jung · 2025 · Blood Research
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
Ilaria Rizzello, Ilaria Sacchetti, Simona Barbato, Vincenza Solli, Patrizia Stefanoni, Lorenzo Cani, Micol Quaresima, Angelo Belotti, Nicola Sgherza, Massimo Gentile et al. · 2025 · Clinical and Experimental Medicine
Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoé, Vânia Hungria, Ângelo Maiolino · 2025 · Blood Cancer Journal
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application
Roberto Mina, Elisabetta Antonioli, Gregorio Barilà, Niccolò Bolli, Cirino Botta, Anna Furlan, Carmine Liberatore, Marina Martello, Sônia Maria Coelho Móre, Stefania Oliva et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
Karun Neupane, Mitch Singstock, Darshi Shah, Riyasha Dahal, Hira S. Mian, Febe Smith, Rajshekhar Chakraborty, Samer S.A. Al Hadidi, Maria Mainou, Ariel Felipe Grajales-Cruz et al. · 2026 · British Journal of Haematology
Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis
Zeng-Yi Huang, Xiao-Lian Liu, Ting Li, Chao-Han Luo · 2026 · Frontiers in Oncology
Multiple Myeloma Management in a Large Low- and Middle-Income Country: Lessons From India in Balancing Cost and Clinical Efficacy in Resource-Limited Settings
Prabhat Gautam Roy, Ajay Gogia, Zain Anwar, Sudipto Mukherjee, Faiz Anwer · 2026 · JCO Oncology Practice
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma
Krzysztof Jamroziak, Dominik Dytfeld, Tadeusz Kubicki, Magdalena Dutka, Tomasz Wróbel, Krzysztof Giannopoulos, Agnieszka Końska, Agnieszka Druzd‐Sitek, Agata Tyczyńska, Magdalena Olszewska‐Szopa et al. · 2026 · British Journal of Haematology
Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients
Manuel David Gil‐Sierra, María Del Pilar Briceño-Casado, Marina Sánchéz‐Hidalgo · 2022 · Supportive Care in Cancer
Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience
Masuho Saburi, Masanori Sakata, Hiroyuki Takata et al. · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
Recent Updates on Multiple Myeloma
Khalid Ahmed Al-Anazi · 2022 · IntechOpen eBooks
Supportive care in multiple myeloma
Artur J. Jurczyszyn, Grzegorz Charliński, David H. Vesole · 2022 · Acta Haematologica Polonica
Initial Therapy of Multiple Myeloma (MM)
J. María Fernández-Rañada de la Gándara · 2023 · ANALES RANM
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study
Jung Yeon Lee, Sung‐Soo Park, Young‐Woo Jeon · 2023 · Journal of Cancer Research and Clinical Oncology